Skip to main content

Indian elections: Why is there no consensus on the next generation of EVMs that could enable remote voting?

To keep you updated, we send ET Sunday Wrap Newsletter to your mailbox. In case, you wish to Unsubscribe Click Here
THE ECONOMIC TIMES
Sun, Apr 30, 2023 | 10:30 AM IST

ET Sunday Wrap

Indian elections: Why is there no consensus on the next generation of EVMs that could enable remote voting?
The prototype of a remote voting machine (RVM), which can handle up to 72 constituencies, has been developed by IITMadras. Remote voting, if agreed upon, could be a tectonic shift in the use of technology in elections.
Wheels are turning back: After two-wheelers lose a decade in India, will this year be different?
It has been a lost decade for two-wheelers in India with a sales CAGR of a little over 1%. Can this year be a turning point? The recent signs of recovery cannot change the fact that the past decade has been a lost one for the two-wheeler segment. The sales inched up from 13.79 million units in FY13 to 15.86 million units in FY23 — a CAGR of 1.4%, the lowest among all vehicle segments.
How smartwatch addiction is driving some wearers to make serious changes to their habits
Smartwatch addiction hits differently compared with smartphone addiction because "while you can physically disconnect from a phone, the watch is tied to your body", says Avneet Kaur, a counselling psychologist with Kaha Mind in Bengaluru. Some can't let go of checking their smartwatches even during therapy sessions, she says.
Sachin: How a teenager with a soft, uncertain voice would become a shrill player at the practice field
With Sachin Tendulkar having turned 50 last Monday, the raspy voice is much more audible. But really, every time I see those twinkling eyes, I remember the sound they produced from the bat.
IITs focus more on mental health as suicides rise
Where intense competition to bag a seat is just the beginning of the battle, and students fight stress, academic performance pressure, depression, homesickness and even discrimination, IITs are stepping up measures to de-stress students and help them cope better.
FM Sitharaman asks CBIC to introduce automated GST return scrutiny by next week
Sitharaman, did a comprehensive review with CBIC and covered a variety of work areas, including trade facilitation, tax payer services, grievance redressal of the trade and finalisation of disciplinary cases and infrastructure projects,
Twitter locks ANI's account for being "under 13 years of age"; NDTV's account locked as well
ANI's editor Smita Prakash announced this in a tweet from her personal handle. Twitter, she said, has also sent an email to ANI stating that the handle was blocked for being "under 13 years of age".
IPL 2023: Gujarat Titans defeat Kolkata Knight Riders by seven wickets, move to top spot
An explosive half-century by Vijay Shankar and classy knocks from Shubman Gill and David Miller powered Gujarat Titans (GT) to a seven-wicket win over Kolkata Knight Riders (KKR) in their Indian Premier League (IPL) match at Eden Gardens in Kolkata on Saturday.
Pep Guardiola keeps focus on Premier League as Real Madrid looms
Manchester City manager Pep Guardiola is ignoring the widely held narrative that his team has pretty much wrapped up another Premier League title and can now start focusing on winning the Champions League for the first time. For Guardiola, one of his biggest challenges now is to keep his players in the present following City's 4-1 win over Arsenal on Wednesday.
View: Tipping, a service industry conundrum of Greek tragedy proportions
By comparison, in France, for example, the waiter pretends he is doing you a favour by serving, when his real skills lie in art, where he will leave Van Gogh in the dust, as soon as he's done clearing up your espresso. In Britain, there's a 10-15% assumption. But it seems like the wait staff are paid well enough. So, they won't shoot you if you didn't tip and ran.
View: India has failed its athletes
When your Olympic champions are on the road protesting for weeks on end, the country is the loser in front of the world. This isn't the idea of India that we stand for. For a country that aspires to host the Olympic Games in a decade and a Youth Olympic Games even earlier, the least it can do is protect the dignity of its athletes.
Meanwhile, making the unprintable printable
A documentary provides a sharp retort to the journalistic circuses we get to see.
Few people are trying to take our movement to a different direction: Bajrang Punia
The protesting wrestlers on Saturday claimed that a few people have entered their movement with a motive to lead it to a different direction but did not clarify who they were. Bajrang Punia, the Tokyo Olympics bronze medallist, said the wrestlers won't let anyone use their platform for political gains.
Harry Kane reaches a fork in the road, and he'll have to take it
Daniel Levy was going for a more flattering vibe. One day last month, Levy, the chairman of Tottenham Hotspur, told the students of the Cambridge University Union that he hoped a statue of Harry Kane would stand outside the club's stadium one day, possibly its greatest-ever striker immortalized in bronze.

Experience your trusted ET newspaper. Now in a brand new way.
The Economic Times print edition. Experience it now with your ET Prime membership.

Read Today's Print Edition
More Newsletters

Daily Newsletter

Special stories that round up the major developments of the day ET More Newsletter

Markets Watch

Round up of stock, currency, bond, money and real estate market ET More Newsletter

ET Investment Opportunities

Property, Stocks, IPOs, NFOs, Mutual Funds and latest investment options in your inbox. ET More Newsletter

Wealth

Weekly news on personal finance, stocks, property, gold, tax planning and more. ET More Newsletter
View All
Follow Us on ET:
Facebook Twitter YouTube LinkedIn
About us| Advertise with us| Feedback| Sitemap| Code of Ethics
© 2023 Times Internet Limited.
To ensure delivery directly to your inbox, please add newsletter@economictimesnews.com to your address book today.
If you are having trouble viewing this newsletter, please click here
To unsubscribe or edit your subscriptions please click here

Comments

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side